Advantages of routine next‐generation sequencing over standard genetic testing in the amyotrophic lateral sclerosis clinic
European Journal of Neurology · 2023
DOI: 10.1111/ene.15855 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2023. Verfasst von Jakub Scaber und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Motor Neurone Disease Association, Medical Research Council, Department of Health.
Abstract (Originalsprache)
Background
Next‐generation sequencing has enhanced our understanding of amyotrophic lateral sclerosis (ALS) and its genetic epidemiology. Outside the research setting, testing is often restricted to those who report a family history. The aim of this study was to explore the added benefit of offering routine genetic testing to all patients in a regional ALS centre.
Methods
C9ORF72 expansion testing and exome sequencing was offered to consecutive patients (150 with ALS and 12 with primary lateral sclerosis [PLS]) attending the Oxford Motor Neuron Disease Clinic within a defined time period.
Results
A total of 17 (11.3%) highly penetrant pathogenic variants in C9ORF72 , SOD1 , TARDBP , FUS and TBK1 were detected, of which 10 were also found through standard clinical genetic testing pathways. The systematic approach resulted in five additional diagnoses of a C9ORF72 expansion (number needed to test [NNT] = 28), and two further missense variants in TARDBP and SOD1 (NNT = 69). Additionally, 3 patients were found to carry pathogenic risk variants in NEK1 , and 13 patients harboured common missense variants in CFAP410 and KIF5A , also associated with an increased risk of ALS. We report two novel non‐coding loss‐of‐function splice variants in TBK1 and OPTN . No relevant variants were found in the PLS patients. Patients were offered double‐blinded participation, but >80% requested disclosure of the results.
Conclusions
This study provides evidence that expanding genetic testing to all patients with a clinical diagnosis of ALS enhances the potential for recruitment to clinical trials, but will have direct resource implications for genetic counselling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
- Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.
ORCID-Profile: Jakub Scaber, Alexander G Thompson, Emily Feneberg
Förderung
- Motor Neurone Disease Association
- Medical Research Council
- Department of Health
- Academy of Medical Sciences
- John Fell Fund, University of Oxford
Zitieren
APA
Scaber, J., Thompson, A. G., Farrimond, L., Feneberg, E., Proudfoot, M., Ossher, L., Turner, M. R., & Talbot, K. (2023). Advantages of routine next‐generation sequencing over standard genetic testing in the amyotrophic lateral sclerosis clinic. European Journal of Neurology. https://doi.org/10.1111/ene.15855
Vancouver
Scaber J, Thompson AG, Farrimond L, Feneberg E, Proudfoot M, Ossher L, et al. Advantages of routine next‐generation sequencing over standard genetic testing in the amyotrophic lateral sclerosis clinic. European Journal of Neurology. 2023. doi:10.1111/ene.15855
BibTeX
@article{Scaber2023,
author = {Scaber, Jakub and Thompson, Alexander G and Farrimond, Lucy and Feneberg, Emily and Proudfoot, Malcolm and Ossher, Lynn and Turner, Martin R and Talbot, Kevin},
title = {Advantages of routine next‐generation sequencing over standard genetic testing in the amyotrophic lateral sclerosis clinic},
journal = {European Journal of Neurology},
year = {2023},
doi = {10.1111/ene.15855}
}
EUVIMED